Work

Supplementary Figure S7 from Comutations and KRASG12C Inhibitor Efficacy in Advanced NSCLC

Year: 2023
Type: supplementary-materials
Abstract: Progression-free survival (left) and overall survival (right) according to co-mutation status for (A) CHEK2 and (B) ATRX in the overall mutation-evaluable population.
Language: English
Field: Medicine
Open Access status: gold
OpenAlex ID: W4383552769
Cites:
Cited by:
Related to: 10